Intech Investment Management LLC Invests $154,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Intech Investment Management LLC bought a new position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,085 shares of the company’s stock, valued at approximately $154,000.

Other hedge funds have also modified their holdings of the company. Candriam S.C.A. acquired a new stake in iTeos Therapeutics during the 2nd quarter valued at $7,558,000. Clearline Capital LP acquired a new stake in iTeos Therapeutics during the 2nd quarter valued at $2,328,000. Dimensional Fund Advisors LP increased its holdings in iTeos Therapeutics by 14.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after purchasing an additional 117,159 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in iTeos Therapeutics during the 3rd quarter valued at $263,000. Finally, Victory Capital Management Inc. increased its holdings in iTeos Therapeutics by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 110,389 shares of the company’s stock valued at $1,638,000 after purchasing an additional 16,629 shares in the last quarter. 97.16% of the stock is owned by institutional investors and hedge funds.

iTeos Therapeutics Stock Performance

Shares of ITOS opened at $8.32 on Friday. iTeos Therapeutics, Inc. has a 52 week low of $7.54 and a 52 week high of $18.75. The firm has a market capitalization of $303.93 million, a price-to-earnings ratio of -2.64 and a beta of 1.37. The business’s fifty day moving average price is $8.92 and its two-hundred day moving average price is $13.31.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.18) by $0.13. As a group, research analysts forecast that iTeos Therapeutics, Inc. will post -3.46 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ITOS. JPMorgan Chase & Co. decreased their price objective on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. HC Wainwright reiterated a “buy” rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a research report on Friday, November 15th. Wedbush reiterated an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research report on Tuesday, November 12th. Finally, Wells Fargo & Company began coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 price objective on the stock.

Insider Transactions at iTeos Therapeutics

In related news, CFO Matthew Gall purchased 5,000 shares of iTeos Therapeutics stock in a transaction dated Tuesday, November 19th. The shares were acquired at an average cost of $7.73 per share, for a total transaction of $38,650.00. Following the transaction, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. This trade represents a 8.27 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 12.50% of the stock is owned by corporate insiders.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.